Pancreatic cancer success story stems from 'undruggable' KRAS target | STAT
Daraxonrasib, a pancreatic cancer drug from Revolution Medicines, is showing unprecedented success. For patients like Leanna Stokes, survival time doubled.
Leanna Stokes had gotten into the habit of asking her oncologist what might be next for her treatment, and for good reason. Stokes, a 36-year-old gymnastics manager from New Rochelle, N.Y., had received one of the most difficult diagnoses in oncology: metastatic pancreatic cancer. Her oncologist kept mentioning two syllables, KAY-ras, referring to her cancer’s mutation on the KRAS gene. Mutations in this gene can make cancers more aggressive. But for Stokes, it was a possible key to extending her life. “She always mentioned this — KRAS, KRAS, KRAS,” Stokes said of her oncologist. As Stokes…
saved by
related reading
- Has pancreatic cancer met its match?worksinprogress.co
- The current state of the art and future trends in RAS-targeted cancer therapiesnature.com
- Weekly Dose of Optimism #208notboring.co
- Pancreatic Cancer - PMCncbi.nlm.nih.gov
- Pancreatic Cancer - StatPearls - NCBI Bookshelfncbi.nlm.nih.gov
- Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance - PMCncbi.nlm.nih.gov
- The blood cancer that became solvableworksinprogress.news
- Cancersytse.com
- Stanford Cancer Institute Breakthroughs in Cancer: Charles Sawyers, MDyoutube.com
- Cure all diseasesworksinprogress.news
- Warpspeed — Forecastswarpspeed.sh
- Medical breakthroughs in 2025 - by Saloni Dattaniscientificdiscovery.dev